Continuous Collection of Stem Cells from a Human Placenta Perfusion Co-Culture
Poster Mar 16, 2015
John J.S. Cadwell & James C. Hardy
The presence of smaller cells in the ECS harvests, OCT3/4 phenotype and the highly proliferative nature of this harvest when placed into flasks suggests the presence of very small embryonic-like stem cells. The hollow fiber cell culture environment is clearly different than flask culture. Three dimensional structures were formed on the surface of the fibers. Cytokine concentration and cell to cell interactions may play a role in their formation. When harvested cells were placed into flasks, the different cell culture environment induced these cells to differentiate into mesenchymal stem cells and generate spheroids. The recapitulation of the placental construct may represent a unique source for continuous culture and collection of stem cells. Hollow fiber bioreactors represent a different cell culture environment with resultant differences in cell phenotype from flask culture. These experiments demonstrate the capability of hollow fiber bioreactors to support continuous production of certain stem cell types in a single use system. Larger scale systems have the potential to produce stem cells on a continuous basis and meet the criteria for their bio-manufacturing in a single-use system on a clinical scale.
Extracorporeal shockwave therapy accelerates motor axon regeneration despite a phenotypically mismatched environmentPoster
A femoral nerve defect model was adapted for the evaluation of proregenerative effects of extracorporeal shockwave therapy (ESWT). Functional evaluation, histology and qRT-PCR data show differences between sensory and motor-derived nerve transplants and a pro-regenerative effect of ESWT. These data provide evidence for the clinical application of ESWT after autologous nerve transplantation as a novel non-invasive method.READ MORE
Histone Deacetylase 6 (HDAC6) As A Therapeutic Target in Chronic Lymphocytic LeukemiaPoster
This study investigates the role of histone deacetylase 6 (HDAC6) in chronic lymphocytic leukemia and establishes it as a novel therapeutic target for the treatment of this disease.READ MORE